Clinical trial
Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and…
NCT00239291 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00239291 |
|---|---|
| Title | Safety Study to Explore Combination of Gefitinib (ZD1839, Iressa) and Radiotherapy in Non-Metastatic Prostate Cancer |
| Official title | A Phase I/II Study of ZD1839 (Iressa) Given Concurrently With Radiotherapy in Patients With Non-Metastatic Prostate Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Metastatic Prostate Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib, radiotherapy |
| Enrollment | 42 |
| Start date | Jan 1, 2003 |
| Completion | May 1, 2006 |
| First posted | Oct 17, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: